We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-8.02%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$259M
AUM Growth
-$35.1M
Cap. Flow
-$4.78M
Cap. Flow %
-1.85%
Top 10 Hldgs %
96.31%
Holding
16
New
1
Increased
5
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$26.3M
2
AMGN icon
Amgen
AMGN
+$9.79M
3
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.96M
4
KIN
Kindred Biosciences, Inc.
KIN
+$2.19M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$2.17M

Top Sells

Rank Stock Value
1
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
+$48.2M
2
LH icon
Labcorp
LH
+$3.87M

Sector Composition

Rank Sector Weight
1 Healthcare 84.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$69.4M 26.8%
12,850,000
+850,000
+7% +$4.96M
DGX icon
2
Quest Diagnostics
DGX
$25.7B
$47M 18.16%
775,000
– –
BRLI
3
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
$35.9M 13.88%
1,280,984
– –
A icon
4
Agilent Technologies
A
$39.1B
$26.2M 10.12%
+643,080
New +$26.3M
MRK icon
5
Merck
MRK
$322B
$23.7M 9.16%
419,200
– –
AMGN icon
6
Amgen
AMGN
$208B
$16.9M 6.51%
120,000
+75,000
+167% +$9.79M
RPRX
7
DELISTED
Repros Therapeutics Inc.
RPRX
$11.2M 4.33%
1,132,367
+129,000
+13% +$1.91M
VVUS
8
DELISTED
Vivus Inc
VVUS
$9.94M 3.84%
257,394
– –
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.94M 1.91%
360,000
+144,798
+67% +$2.17M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$366M
$4.16M 1.6%
105,000
– –
KIN
11
DELISTED
Kindred Biosciences, Inc.
KIN
$3.61M 1.39%
390,000
+161,874
+71% +$2.19M
AVEO
12
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.85M 1.1%
257,076
– –
GYRE icon
13
Gyre Therapeutics
GYRE
$641M
$1.59M 0.62%
800
– –
TRAW icon
14
Traws Pharma
TRAW
$6.85M
$1.5M 0.58%
6
– –
LH icon
15
Labcorp
LH
$25.4B
– –
-44,027
Closed -$3.87M
IDIX
16
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
– –
-2,000,000
Closed -$48.2M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sarissa Capital Management held 16 positions worth $259M, down 12% from $294M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Sarissa Capital Management's Q3 2014 filing shows 1 new, 5 increased and 2 closed positions. Its largest new stake was Agilent Technologies: 643,080 shares worth $26.2M. The largest sale was IDENIX PHARMACEUTICALS INC, an estimated $48.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 69% a quarter earlier.

  • Sarissa Capital Management's largest Q3 2014 buy was Agilent Technologies: 643,080 shares worth $26.2M.
  • Sarissa Capital Management added most to Amgen in Q3 2014, an estimated $9.79M increase.
  • Sarissa Capital Management fully exited IDENIX PHARMACEUTICALS INC in Q3 2014, selling an estimated $48.2M.
  • Sarissa Capital Management's ten largest holdings make up 96% of its $259M portfolio in Q3 2014.
  • Sarissa Capital Management opened 1 new position and closed 2 in Q3 2014.
  • Sarissa Capital Management's portfolio value fell 12% quarter-over-quarter to $259M.

Based on Sarissa Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.